🇺🇸 FDA
Pipeline program

evinacumab

R1500-HTG-1522

Phase 2 small_molecule completed

Quick answer

evinacumab for Severe Hypertriglyceridemia (sHTG) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Severe Hypertriglyceridemia (sHTG)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials